000			01520 a2200457 4500
005			20250511184715.0
264		0	_c19930107
008			199301s 0 0 eng d
022			_a0340-6245
040			_aNLM _beng _cNLM
100	1		_aRyan, K E
245	0	0	_aAntithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. _h[electronic resource]
260			_bThrombosis and haemostasis _cNov 1992
300			_a563-9 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntithrombin III _xmetabolism
650	0	4	_aBlood Coagulation _xdrug effects
650	0	4	_aDermatan Sulfate _xadministration & dosage
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aFemale
650	0	4	_aFibrinolytic Agents _xtherapeutic use
650	0	4	_aFibrinopeptide A _xmetabolism
650	0	4	_aHeparin _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aKidney Failure, Chronic _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPeptide Hydrolases _xmetabolism
650	0	4	_aRenal Dialysis
650	0	4	_aThrombosis _xprevention & control
700	1		_aLane, D A
700	1		_aFlynn, A
700	1		_aIreland, H
700	1		_aBoisclair, M
700	1		_aShepperd, J
700	1		_aCurtis, J R
773	0		_tThrombosis and haemostasis _gvol. 68 _gno. 5 _gp. 563-9
999			_c1461892 _d1461892